Lyell director granted 9,250 stock options
Lyell Immunopharma director Otis W. Brawley reported a new stock option grant.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Lyell Immunopharma director Otis W. Brawley reported a new stock option grant. He received options to buy 9,250 shares of common stock at an exercise price of $13.22 per share, expiring on June 9, 2036.
The options vest on the earlier of the next annual stockholder meeting after June 10, 2026 or the first anniversary of that date, subject to his continued service as a director. Following the reported transactions, he holds 1,782 shares of common stock directly. All share amounts reflect a 1-for-20 reverse stock split effective May 30, 2025.
Insider Trade Summary
Grant/Award: 9,250 shares
Grant/Award
2 txns
Insider
BRAWLEY OTIS W
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option (right to buy) | 9,250 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 9,250 contracts (Direct);
Common Stock — 1,782 shares (Direct)
Footnotes (2)
- F1. On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.
- F2. The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.
Key Figures
Option grant size: 9,250 options
Exercise price: $13.22/share
Option expiration: June 9, 2036
+2 more
5 metrics
Option grant size
9,250 options
Director stock option grant on common stock
Exercise price
$13.22/share
Exercise price of granted options
Option expiration
June 9, 2036
Expiration date of director options
Common shares held
1,782 shares
Common stock held directly after transactions
Reverse stock split ratio
1-for-20
Reverse split effective May 30, 2025
Key Terms
reverse stock split, Option (right to buy), exercise price, grant, award, or other acquisition, +1 more
5 terms
reverse stock split financial
"On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock."
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
Option (right to buy) financial
"Option (right to buy) transaction covering 9,250.0000 derivative shares."
exercise price financial
"conversion_or_exercise_price: 13.2200 per share on the granted options."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition."
vesting financial
"The option shares shall vest on the earlier of the next annual meeting or the first anniversary of June 10, 2026."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Lyell Immunopharma (LYEL) director Otis W. Brawley report on this Form 4?
He reported a grant of options for 9,250 shares of Lyell Immunopharma common stock at a $13.22 exercise price. The filing also shows he directly holds 1,782 common shares after the reported transactions, reflecting the company’s recent 1-for-20 reverse stock split.
What are the key terms of Otis W. Brawley’s new Lyell (LYEL) stock options?
The options cover 9,250 shares of common stock with a $13.22 per-share exercise price and expire on June 9, 2036. They were granted as a compensation award and relate to underlying Lyell Immunopharma common stock on a post–reverse split basis.
When do Otis W. Brawley’s Lyell Immunopharma (LYEL) options vest?
They vest on the earlier of the next annual stockholder meeting after June 10, 2026, or the first anniversary of June 10, 2026. Vesting is conditioned on Brawley providing continuous service as a director through the applicable vesting date described in the grant terms.
How did Lyell Immunopharma’s reverse stock split affect the figures in this Form 4?
Lyell Immunopharma completed a 1-for-20 reverse stock split of its common stock on May 30, 2025. All share amounts and option figures in this Form 4, including the 9,250 options and 1,782 shares held, are already adjusted to reflect that reverse split ratio.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates